IonQ Announces Third Quarter 2022 Financial Results
IonQ announced third quarter 2022 results with revenue of $2.8 million and bookings of $16.4 million, indicating strong business momentum. The company secured a groundbreaking $13.4 million contract with the U.S. Air Force Research Lab, enhancing its public-private collaboration in quantum technology. IonQ achieved a technical milestone of 25 algorithmic qubits, a fourfold increase in the power of its Aria system. For Q4, IonQ expects revenue between $2.9 million and $3.4 million, maintaining its full-year revenue outlook of $10.2 million to $10.7 million.
- Third quarter revenue increased to $2.8 million from $233 thousand year-over-year.
- Achieved bookings of $16.4 million in the third quarter.
- Signed a significant $13.4 million contract with the U.S. Air Force Research Lab.
- Technical milestone of 25 qubits achieved, increasing Aria's computational power by 4x.
- Maintained full-year revenue guidance of $10.2 million to $10.7 million.
- Net loss increased to $24 million in Q3 2022.
- Adjusted EBITDA was ($13.4 million), indicating ongoing financial challenges.
Third Quarter Results of
Signs Groundbreaking
Achieves 2022 Technical Milestone of 25 Algorithmic Qubits,
Maintains 2022 Full Year Guidance
“During the quarter, we announced a
“This morning, we announced that
Third Quarter 2022 Financial Highlights
-
IonQ recognized revenue of for the third quarter, above the midpoint of the previously provided range, compared to$2.8 million in the prior year period.$233 thousand
-
IonQ achieved bookings of for the third quarter. As$16.4 million IonQ has noted on prior calls, management continues to expect bookings to be lumpy for quite some time.
-
Cash, cash equivalents and investments were
as of$555.8 million September 30, 2022 .
-
Net loss was
and Adjusted EBITDA was$24.0 million ( .* Excluded from Adjusted EBITDA is, among other adjustments, a non-cash loss of$13.4) million related to the change in the fair value of IonQ’s warrant liabilities.*$1.2 million
* Adjusted EBITDA is a non-GAAP financial measure defined under “Non-GAAP Financial Measures,” and is reconciled to net loss, its closest comparable GAAP measure, at the end of this release.
Commercial Highlights
-
In September, the
United States Air Force Research Lab (AFRL) announced a multi-part, contract with$13.4 million IonQ .IonQ will supply cloud access to compute on its cutting-edge trapped ion systems and certain hardware components to further research in quantum networking.
-
IonQ announced a project with theOak Ridge National Laboratory , part of theU.S. Department of Energy , to research benchmark circuits for the discovery of new quantum chemistry applications.
-
IonQ announced a new partnership with Dell Technologies to offer joint customers a world-class hybrid computing solution, allowing for the seamless transitioning of workloads between the world’s leading quantum and classical computing hardware systems.
Technical Highlights
-
IonQ increased the computational power of its Aria system by approximately 4x, now reaching #AQ 25, up from #AQ 23. Aria was already believed to be the most powerful quantum computer known, and has now achieved IonQ’s #AQ technical milestone for 2022. Aria is available to the public via cloud access on Microsoft’s Azure Quantum Cloud.
-
IonQ announced a next generation custom chip called the multilayered glass trap (MGT), which utilizes multiple layers to route wires across the chip to enable higher qubit count per chip.
2022 Financial Outlook
-
For the fourth quarter of 2022,
IonQ is expecting revenue of between and$2.9 million .$3.4 million
-
For the full year 2022,
IonQ is reiterating the previously stated revenue outlook range of to$10.2 million .$10.7 million
-
IonQ is maintaining its previously stated bookings range of to$23 million for the full year 2022.$27 million
-
IonQ notes thatUnited States government investment in quantum information science R&D nearly doubled from 2019 to 2022, going from a reported to a requested$449 million .$877 million
Third Quarter 2022 Conference Call
Non-GAAP Financial Measures
To supplement IonQ’s condensed consolidated financial statements presented in accordance with GAAP, we use non-GAAP measures of certain components of financial performance. Adjusted EBITDA is a financial measure that is not required by or presented in accordance with GAAP. Management believes that this measure provides investors an additional meaningful method to evaluate certain aspects of the company’s results period over period. Adjusted EBITDA is defined as net loss before interest income, net, interest expense, benefit from income taxes, depreciation and amortization expense, stock-based compensation, change in fair value of assumed warrant liabilities, offering cost associated with warrants, and other non-recurring non-operating income and expenses.
About
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward- looking words. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the Company’s ability to further develop and advance its quantum computers and achieve scale, including by continuing to improve its algorithmic qubits at the same pace or at all; the potential benefits of quantum computing and IonQ’s collaborations and partnerships, including its new partnership with Dell Technologies, contract with the AFRL and/or project with
Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data) |
||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
|
|
|
||||||||||||||
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||||
Revenue |
$ |
2,763 |
|
$ |
233 |
|
$ |
7,324 |
|
$ |
451 |
|
||||
Costs and expenses: |
|
|
|
|
||||||||||||
Cost of revenue (excluding depreciation and amortization) |
|
733 |
|
|
234 |
|
|
2,043 |
|
|
742 |
|
||||
Research and development |
|
13,292 |
|
|
6,180 |
|
|
30,282 |
|
|
15,311 |
|
||||
Sales and marketing |
|
1,969 |
|
|
1,286 |
|
|
5,971 |
|
|
2,384 |
|
||||
General and administrative |
|
10,149 |
|
|
2,461 |
|
|
26,901 |
|
|
8,321 |
|
||||
Depreciation and amortization |
|
1,531 |
|
|
596 |
|
|
4,248 |
|
|
1,543 |
|
||||
Total operating costs and expenses |
|
27,674 |
|
|
10,757 |
|
|
69,445 |
|
|
28,301 |
|
||||
Loss from operations |
|
(24,911 |
) |
|
(10,524 |
) |
|
(62,121 |
) |
|
(27,850 |
) |
||||
Change in fair value of warrant liabilities |
|
(1,151 |
) |
|
— |
|
|
28,358 |
|
|
— |
|
||||
Interest income, net |
|
2,059 |
|
|
— |
|
|
3,926 |
|
|
— |
|
||||
Offering costs associated with warrants |
|
— |
|
|
(4,259 |
) |
|
— |
|
|
(4,259 |
) |
||||
Other income (expense), net |
|
20 |
|
|
2 |
|
|
(27 |
) |
|
7 |
|
||||
Loss before benefit for income taxes |
|
(23,983 |
) |
|
(14,781 |
) |
|
(29,864 |
) |
|
(32,102 |
) |
||||
Benefit for income taxes |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
Net loss |
$ |
(23,983 |
) |
$ |
(14,781 |
) |
$ |
(29,864 |
) |
$ |
(32,102 |
) |
||||
Net loss per share attributable to common stockholders - basic and diluted |
$ |
(0.12 |
) |
$ |
(0.12 |
) |
$ |
(0.15 |
) |
$ |
(0.27 |
) |
||||
Weighted average shares used in computing net loss per share attributable to common stockholders - basic and diluted |
|
198,301,240 |
|
|
120,605,457 |
|
|
197,255,965 |
|
|
119,535,167 |
|
Condensed Consolidated Balance Sheets (unaudited) (in thousands) |
||||||||
|
2022 |
|
2021 |
|||||
Assets: |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ |
57,198 |
|
$ |
399,025 |
|
||
Short-term investments |
|
348,435 |
|
|
123,443 |
|
||
Accounts receivable |
|
2,876 |
|
|
707 |
|
||
Prepaid expenses and other current assets |
|
8,134 |
|
|
6,442 |
|
||
Total current assets |
|
416,643 |
|
|
529,617 |
|
||
Long-term investments |
|
150,154 |
|
|
80,110 |
|
||
Property and equipment, net |
|
25,065 |
|
|
18,870 |
|
||
Operating lease right-of-use assets |
|
3,824 |
|
|
4,032 |
|
||
Intangible assets, net |
|
7,600 |
|
|
5,841 |
|
||
Other noncurrent assets |
|
3,315 |
|
|
3,558 |
|
||
Total Assets |
$ |
606,601 |
|
$ |
642,028 |
|
||
Liabilities and Stockholders’ Equity: |
|
|
||||||
Current liabilities: |
|
|
||||||
Accounts payable |
$ |
5,042 |
|
$ |
1,882 |
|
||
Accrued expenses |
|
8,177 |
|
|
2,647 |
|
||
Current portion of operating lease liabilities |
|
582 |
|
|
568 |
|
||
Unearned revenue |
|
4,700 |
|
|
3,430 |
|
||
Current portion of stock option early exercise liabilities |
|
1,130 |
|
|
1,164 |
|
||
Total current liabilities |
|
19,631 |
|
|
9,691 |
|
||
Operating lease liabilities, net of current portion |
|
3,512 |
|
|
3,643 |
|
||
Unearned revenue, net of current portion |
|
741 |
|
|
1,533 |
|
||
Stock option early exercise liabilities, net of current portion |
|
1,122 |
|
|
1,969 |
|
||
Warrant liabilities |
|
5,598 |
|
|
33,962 |
|
||
Other noncurrent liabilities |
|
367 |
|
|
— |
|
||
Total liabilities |
$ |
30,971 |
|
$ |
50,798 |
|
||
Stockholders’ Equity: |
|
|
||||||
Common stock |
|
20 |
|
|
19 |
|
||
Additional paid-in capital |
|
760,389 |
|
|
737,150 |
|
||
Accumulated deficit |
|
(175,655 |
) |
|
(145,791 |
) |
||
Accumulated other comprehensive loss |
|
(9,124 |
) |
|
(148 |
) |
||
Total stockholders’ equity |
|
575,630 |
|
|
591,230 |
|
||
Total Liabilities and Stockholders’ Equity |
$ |
606,601 |
|
$ |
642,028 |
|
Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) |
||||||||
|
||||||||
|
Nine Months Ended |
|||||||
|
|
|||||||
|
2022 |
|
2021 |
|||||
Cash flows from operating activities: |
|
|||||||
Net loss |
$ |
(29,864 |
) |
$ |
(32,102 |
) |
||
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
||||||
Depreciation and amortization |
|
4,248 |
|
|
1,543 |
|
||
Non-cash research and development arrangements |
|
390 |
|
|
1,205 |
|
||
Amortization of customer warrant |
|
— |
|
|
219 |
|
||
Stock-based compensation expense |
|
22,561 |
|
|
5,929 |
|
||
Change in fair value of warrant liabilities |
|
(28,358 |
) |
|
— |
|
||
Offering costs associated with warrants |
|
— |
|
|
4,259 |
|
||
Other, net |
|
(38 |
) |
|
184 |
|
||
Changes in operating assets and liabilities: |
|
|
||||||
Accounts receivable |
|
(1,135 |
) |
|
(3,691 |
) |
||
Prepaid expenses and other current assets |
|
(1,842 |
) |
|
(3,950 |
) |
||
Accounts payable |
|
2,992 |
|
|
(1,191 |
) |
||
Accrued expenses |
|
1,996 |
|
|
1,714 |
|
||
Unearned revenue |
|
(555 |
) |
|
4,084 |
|
||
Other assets and liabilities |
|
(180 |
) |
|
(54 |
) |
||
Net cash used in operating activities |
|
(29,785 |
) |
|
(21,851 |
) |
||
Cash flows from investing activities: |
|
|
||||||
Purchases of property and equipment |
|
(8,381 |
) |
|
(5,295 |
) |
||
Capitalized software development costs |
|
(1,491 |
) |
|
(1,205 |
) |
||
Intangible asset acquisition costs |
|
(598 |
) |
|
(414 |
) |
||
Purchases of available-for-sale securities |
|
(488,887 |
) |
|
— |
|
||
Maturities and sales of available-for-sale securities |
|
185,150 |
|
|
— |
|
||
Net cash used in investing activities |
|
(314,207 |
) |
|
(6,914 |
) |
||
Cash flows from financing activities: |
|
|
||||||
Proceeds from stock options exercised |
|
953 |
|
|
5,424 |
|
||
Tax withholding receipts related to vested and released restricted stock units |
|
1,212 |
|
|
— |
|
||
Tax withholding payments related to vested and released restricted stock units |
|
(17 |
) |
|
— |
|
||
Proceeds from public warrants exercised |
|
17 |
|
|
— |
|
||
Repurchase of early exercised stock options |
|
— |
|
|
(968 |
) |
||
Proceeds from merger and PIPE transaction, net of transaction costs |
|
— |
|
|
575,483 |
|
||
Net cash provided by financing activities |
|
2,165 |
|
|
579,939 |
|
||
Net change in cash and cash equivalents |
|
(341,827 |
) |
|
551,174 |
|
||
Cash and cash equivalents at the beginning of the period |
|
399,025 |
|
|
36,120 |
|
||
Cash and cash equivalents at the end of the period |
$ |
57,198 |
|
$ |
587,294 |
|
Reconciliation of Net Loss to Adjusted EBITDA (unaudited) (in thousands) |
||||||||||||||||
|
||||||||||||||||
Three Months Ended |
|
Nine Months Ended |
||||||||||||||
|
|
|
|
|||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|||||||||
Net loss |
$ |
(23,983 |
) |
$ |
(14,781 |
) |
$ |
(29,864 |
) |
$ |
(32,102 |
) |
||||
Interest income, net |
|
(2,059 |
) |
|
— |
|
|
(3,926 |
) |
|
— |
|
||||
Interest expense |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
Benefit for income taxes |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
Depreciation and amortization expense |
|
1,531 |
|
|
596 |
|
|
4,248 |
|
|
1,543 |
|
||||
Stock-based compensation |
|
10,005 |
|
|
2,055 |
|
|
22,561 |
|
|
5,929 |
|
||||
Change in fair value of assumed warrant liabilities |
|
1,151 |
|
|
— |
|
|
(28,358 |
) |
|
— |
|
||||
Offering cost associated with warrants |
|
— |
|
|
4,259 |
|
|
— |
|
|
4,259 |
|
||||
Adjusted EBITDA |
$ |
(13,355 |
) |
$ |
(7,871 |
) |
$ |
(35,339 |
) |
$ |
(20,371 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005783/en/
IonQ Media Contact:
press@ionq.com
IonQ Investor Contact:
investors@ionq.com
Source:
FAQ
What were IonQ's third quarter 2022 earnings results?
What are IonQ's expectations for Q4 2022?
How much did IonQ book in contracts during the third quarter?
What technical milestones did IonQ achieve in 2022?